Onglyza News and Research

RSS
Incretin-based drugs do not increase risk of heart failure

Incretin-based drugs do not increase risk of heart failure

Bristol-Myers Squibb fourth quarter 2013 revenues increase 6% to $4.4 billion

Bristol-Myers Squibb fourth quarter 2013 revenues increase 6% to $4.4 billion

Bristol-Myers Squibb signs agreement to sell global diabetes business

Bristol-Myers Squibb signs agreement to sell global diabetes business

Bristol-Myers Squibb and AstraZeneca announce top line results of Phase 4 SAVOR-TIMI-53 clinical trial of Onglyza

Bristol-Myers Squibb and AstraZeneca announce top line results of Phase 4 SAVOR-TIMI-53 clinical trial of Onglyza

EU approves Forxiga for treatment of type 2 diabetes

EU approves Forxiga for treatment of type 2 diabetes

Bristol-Myers Squibb completes acquisition of Amylin

Bristol-Myers Squibb completes acquisition of Amylin

Bristol-Myers Squibb to acquire Amylin

Bristol-Myers Squibb to acquire Amylin

European Commission approves ONGLYZA as combination therapy with insulin for type 2 diabetes

European Commission approves ONGLYZA as combination therapy with insulin for type 2 diabetes

ONGLYZA used with insulin maintains improvement in glucose control in adults with type 2 diabetes

ONGLYZA used with insulin maintains improvement in glucose control in adults with type 2 diabetes

Bristol-Myers Squibb first quarter net sales increase 5% to $3.3 billion

Bristol-Myers Squibb first quarter net sales increase 5% to $3.3 billion

European Commission approves BMY's ONGLYZA to treat type 2 diabetes

European Commission approves BMY's ONGLYZA to treat type 2 diabetes

FDA approves ONGLYZA to treat type 2 diabetes patients with renal impairment

FDA approves ONGLYZA to treat type 2 diabetes patients with renal impairment

FDA approved KOMBIGLYZE XR for type 2 diabetes mellitus now available in pharmacies

FDA approved KOMBIGLYZE XR for type 2 diabetes mellitus now available in pharmacies

Bristol-Myers Squibb 2010 third quarter U.S. net sales increases 4% to $3.1 billion

Bristol-Myers Squibb 2010 third quarter U.S. net sales increases 4% to $3.1 billion

Bristol-Myers Squibb second-quarter net sales increase 2% to $4.8 billion

Bristol-Myers Squibb second-quarter net sales increase 2% to $4.8 billion

Study: ONGLYZA and metformin improve HbA1c levels for adult patients with type 2 diabetes at 76-weeks

Study: ONGLYZA and metformin improve HbA1c levels for adult patients with type 2 diabetes at 76-weeks

Bristol-Myers Squibb reports 11% increase in first-quarter 2010 revenue

Bristol-Myers Squibb reports 11% increase in first-quarter 2010 revenue

ONGLYZA-metformin combination: FDA accepts NDA for review

ONGLYZA-metformin combination: FDA accepts NDA for review

Bristol-Myers Squibb, AstraZeneca commence SAVOR-TIMI 53 trial of ONGLYZA for type 2 diabetes

Bristol-Myers Squibb, AstraZeneca commence SAVOR-TIMI 53 trial of ONGLYZA for type 2 diabetes

Bristol-Myers Squibb to review key accomplishments at meeting with investment community

Bristol-Myers Squibb to review key accomplishments at meeting with investment community